Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

UCA1 copy number gain in serum cfDNA predicts next-generation antiandrogen resistance in metastatic castration-resistant prostate cancer.

Scientific reports·2026
Same author

Association of CMTM6 expression with clinicopathological characteristics and prognostic implications in renal cell carcinoma.

Therapeutic advances in medical oncology·2026
Same author

Intraprostatic PSMA PET/MRI parameters and clinical markers for ISUP prediction and postoperative biochemical recurrence in patients with primary prostate cancer.

European journal of nuclear medicine and molecular imaging·2026
Same author

Positron Emission Tomography/Computed Tomography Imaging with [<sup>18</sup>F]PARPi for Precision Guidance of Poly ADP-ribose Polymerase Inhibitor Therapy in Homologous Recombination Repair Mutated and Nonmutated Metastatic Castration-resistant Prostate Cancer.

European urology oncology·2026
Same author

[<sup>177</sup>Lu]Lu-PSMA radioligand therapy in systemic therapy-naïve metastatic hormone-sensitive prostate cancer patients: a retrospective study.

European journal of nuclear medicine and molecular imaging·2026
Same author

Quantitative dual-tracer PET/CT biomarkers correlate concordant lesion uptake with PSMA-RLT outcomes in mCRPC: a dual-center study.

European journal of nuclear medicine and molecular imaging·2026

Related Experiment Video

Updated: Jun 27, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer : Joint

Siroos Mirzaei1, Gregor Schweighofer-Zwink2, Heidemarie Ofner3,4

  • 1Department of Nuclear Medicine with PET Center, Clinic Ottakring, Vienna, Austria.

Wiener Klinische Wochenschrift
|June 4, 2025
PubMed
Summary

Prostate-specific membrane antigen (PSMA)-based theranostics are revolutionizing prostate cancer care. This statement highlights their crucial role in precision oncology for managing metastatic castration-resistant prostate cancer.

Keywords:
177LU-PSMAProstate CancerRadioligand therapyTheranostic

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Related Experiment Videos

Last Updated: Jun 27, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Area of Science:

  • Oncology
  • Radiopharmaceuticals
  • Molecular Imaging

Background:

  • Prostate cancer (PCa) is a significant cause of male morbidity and mortality, with rising incidence across age groups.
  • Metastatic castration-resistant prostate cancer (mCRPC) management has been transformed by PSMA-based theranostics.
  • A growing body of literature supports the clinical utility of PSMA theranostics.

Framework:

  • PSMA theranostics utilize PSMA-targeting radiopharmaceuticals for integrated diagnostic and therapeutic applications.
  • This approach enables personalized treatment strategies in precision oncology.
  • The framework encompasses both imaging and therapeutic modalities.

Implementation:

  • PSMA theranostics are integral in managing patients with mCRPC.
  • Clinical application requires a consensus-driven approach.
  • This joint statement provides a practical perspective on current modalities.

Implications:

  • Enhanced awareness of PSMA theranostics is critical for contemporary cancer care.
  • These modalities offer a powerful tool for precision oncology.
  • The consensus-driven approach aims to optimize clinical application and patient outcomes.